[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-384213-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-384213-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","investigate-the-possibility-of-using-phosphorescence-in-clinical-oncology-as-an-early-prognostic-test-in-detecting-brain-carcinogenesis","Investigate the Possibility of Using Phosphorescence in Clinical Oncology as an Early Prognostic Test in Detecting Brain Carcinogenesis","","Phosphorescence is assessed as a non-invasive approach for early prognostic evaluation in clinical oncology, focusing on glioblastoma by studying molecular energy and L-tryptophan metabolism through the kynurenine pathway to support insights into immunity regulation and neuronal function. The feasibility analysis targets 1,039 retrospectively followed patients operated between 2014 and 2022 in participating institutions in Ukraine. A two-step protein phosphorescence detection workflow measures serum phosphorescence intensity after light activation using spectrofluorimetric and spectral selection procedures, aiming to enable predictive models and support patient-centered precision medicine decisions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/investigate-the-possibility-of-using-phosphorescence-in-clinical-oncology-as-an-early-prognostic-test-in-detecting-brain-carcinogenesis/384213/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/investigate-the-possibility-of-using-phosphorescence-in-clinical-oncology-as-an-early-prognostic-test-in-detecting-brain-carcinogenesis/384213.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of using phosphorescence in this study?","Question",{"text":63,"@type":64},"To evaluate the feasibility of phosphorescence in clinical oncology as an early prognostic test for detecting glioblastoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was phosphorescence detection performed in the study?",{"text":68,"@type":64},"The workflow used a two-step method: activating serum phosphorescence with a light source, then measuring intensity via a spectrofluorimeter approach with wavelength selection (e.g., 297–434 nm).",{"name":70,"@type":61,"acceptedAnswer":71},"Why is L-tryptophan metabolism and the kynurenine pathway relevant to glioblastoma assessment?",{"text":72,"@type":64},"Tryptophan degradation via the kynurenine pathway produces metabolites linked to malignant conversion and tumor progression, and phosphorescent fingerprints may help detect cancer activity across organs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},384213,1790717397,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Journal of Fluorescence (2023) 33:2441–2449  \n[https://doi.org/10.1007/s10895-023-03237-9](https://doi.org/10.1007/s10895-023-03237-9)  \nInvestigate the Possibility of Using Phosphorescence in Clinical  \nOncology as an Early Prognostic Test in Detecting Brain Carcinogenesis  \nYuriy O. Vinnyk1 · Igor A. Kryvoruchko2 · Valeriy V. Boyko3,4 · Yulia V. Ivanova4 · Svetlana Gramatiuk5,6 · Karine Sargsyan6,7,8  \nReceived: 7 March 2023 / Accepted: 31 March 2023 / Published online: 27 April 2023 © The Author(s) 2023  \nAbstract  \nPhosphorescence is considered one of the non-invasive glioblastoma testing methods based on studying molecular energy and the metabolism of L-tryptophan (Trp) through KP, which provides essential information on regulating immunity and neuronal function. This study aimed to conduct a feasibility study using phosphorescence in clinical oncology as an early prognostic test in detecting Glioblastoma. This study was conducted on 1039 patients who were operated on with follow-up between January 1, 2014, and December 1, 2022, and retrospectively evaluated in participating institutions in Ukraine (the Department of Oncology, Radiation Therapy, Oncosurgery, and Palliative Care atthe Kharkiv National Medical University) . Method of protein phosphorescence detection included two steps. During the first step, of luminol-dependent phosphorescence intensity in serum was carried out after its activation by the light source, according to the spectrofluorimeter method, as follows. At a temperature of 30 °C, serum drops were dried for 20 min to form a solid film. After that, we put the quartz plate with dried serum in a phosphoroscope of luminescent complex and measured the intensity. With the help of Max-Flux Diffraction Optic Parallel Beam Graded Multilayer Monochromator (Rigaku Americas Corporation) following spectral lines as 297, 313, 334, 365, 404, and 434 nm were distinguished and absorbed by serum film in the form of light quantum. The monochromator exit split width was 0.5 mm. Considering the limitations of each of the non-invasive tools currently available, phosphorescence-based diagnostic methods are ideally integrated into the NIGT platform: a non-invasive approach for visualizing a tumor and its main tumor characteristics in the spatial and temporal order. Because trp is present in virtually every cell in the body, these fluorescent and phosphorescent fingerprints can be used to detect cancer in many different organs. Using phosphorescence, it is possible to create predictive models for GBM in both primary and secondary diagnostics. This will assist clinicians in selecting the appropriate treatment option, monitoring treatment, and adapting to the era of patient-centered precision medicine.  \nKeywords Phosphorescence · Non-invasive glioblastoma testing · L-tryptophan · Cancerous brain tissues  \nAbbreviations  \nCHP Conditionally healthy people  \nCT Computed tomography  \nGB Glioblastoma  \nIDH Isocitrate dehydrogenase Kyn Kynurenine  \nKP Kynurenine Pathway  \nMGB  \nMGMT  \nMRI  \nNADH  \nNIGT  \nTrp  \nMultiforme Glioblastome  \nO6-methylguanine-DNA methyltransferase Magnetic resonance imaging Nicotinamide adenine dinucleotide  \nNon-invasive glioblastoma testing  \nL-tryptophan  \n* Igor A. Kryvoruchko [ikryvoruchko60@gmail.com](ikryvoruchko60@gmail.com)  \n* Svetlana Gramatiuk [gramatyuk@ukrainebiobank.com](gramatyuk@ukrainebiobank.com)  \nExtended author information available on the last page of the article  \nIntroduction  \nGlioblastoma (GBM) is the most aggressive primary brain tumor, with an incidence of 2–3 cases per 100,000 people [1] . The average survival in Ukraine of about 12–14 months is achieved with intensive multimodal treatment, but the number of such patients is minimal. Despite such intensive treatment, there is no cure, and the recurrence of Glioblastoma is inevitable [2] .  \nApproaches to diagnosing GBM are rapidly evolving and are based on the recently revised WHO (2016) criteria for classifying central nervous","cbCaidXmfRrz31ik","https://ap.wps.com/l/cbCaidXmfRrz31ik","pdf",1129119,"English","# Abstract\n# Keywords\n# Abbreviations\n# Introduction\n## Glioblastoma background and diagnosis\n## Metabolic pathways and non-invasive glioblastoma testing","[{\"question\":\"What is the main goal of using phosphorescence in this study?\",\"answer\":\"To evaluate the feasibility of phosphorescence in clinical oncology as an early prognostic test for detecting glioblastoma.\"},{\"question\":\"How was phosphorescence detection performed in the study?\",\"answer\":\"The workflow used a two-step method: activating serum phosphorescence with a light source, then measuring intensity via a spectrofluorimeter approach with wavelength selection (e.g., 297–434 nm).\"},{\"question\":\"Why is L-tryptophan metabolism and the kynurenine pathway relevant to glioblastoma assessment?\",\"answer\":\"Tryptophan degradation via the kynurenine pathway produces metabolites linked to malignant conversion and tumor progression, and phosphorescent fingerprints may help detect cancer activity across organs.\"}]","Investigate the Possibility of Using Phosphorescence in Clinical Oncology as an Early Prognostic Test in Detecting Brain Carcinogenesis | PDF",1790261700,23]